
Journal of Medicinal Chemistry p. 604 - 608 (1989)
Update date:2022-07-30
Topics:
Thurston
Imakura
Haruna
Li
Liu
Liu
Cheng
Lee
A principal mechanism of action of the clinical antitumor drugs etoposide (1) and teniposide (2) is the inhibition of catalytic activity of type II DNA topoisomerase and concurrent enzyme-mediated production of lethal DNA strand breaks. Substitution of the glycosidic moiety of 1 or 2 by ester and ethers, as well as the esterification and etherification of α-peltatin (4) including its glucosidic ethylidene and thenylidene cyclic acetals (25 and 26), has afforded compounds of much less activity than that of 1. The in vitro cytotoxicity (KB) appears to have no correlation with the inhibitory activity of the human DNA topoisomerase II.
View MoreContact:0086-22-2822 1962 / 2822 1963
Address:B-808, No. 1, North-South Street, Hexi District,
Beyond Pharmaceutical Co., Ltd
Contact:+86-571-8195-3185
Address:No. 13-1, Liansheng Road, Yuhang District
Xiamen XM-Innovation Chemical Co., Ltd
Contact:+86-592-3216205
Address:Unit Q, 11/F, No.1 Office Building, Wuyuan Bay Business Center, Huli District, Xiamen City, Fujian Province, P.R.C
Contact:+86-633-8332928
Address:No.1,Huanghai Yilu.Rizhao,Shandong
Contact:13813902930 025-52714267
Address:20 Fengji Road, Yuhua Economic Development Zone, Nanjing, Jiangsu, P. R. China
Doi:10.1021/jo01091a039
(1959)Doi:10.1021/ja01564a058
(1957)Doi:10.1007/BF03251529
(1956)Doi:10.1039/c39950001139
(1995)Doi:10.1016/j.bmc.2008.01.018
(2008)Doi:10.1021/ol301916t
(2012)